Managing the side effects of therapy

Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future

Volumn , Issue , 2012, Pages 171-182

  Cooper, Curtis ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adverse events; Cytopenias; Depression; Mental health; Neurocognitive; Pegylated interferon; Rash; Ribavirin; Side effects

Indexed keywords

EID: 84892174560     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1192-5_14     Document Type: Chapter

References (57)

1. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-92.
2. Poynard T, Slama G, Delage A, Tchobroutsky G. Pectin efficacy in insulin-treated diabetics assessed by the artificial pancreas. Lancet. 1980;1(8160):158.
3. Legha SS. Current therapy for malignant melanoma. Semin Oncol. 1989;16(1 Suppl 1):34-44.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13): 975-82.
5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666-72.
6. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2): 395-403.
7. Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health Qual Life Outcomes. 2006;4:30.
8. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis. 2004;24 Suppl 2:97-104.
9. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumininterferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol. 2006;44(4):671-8.
10. Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008;48(2):407-17.
11. Poordad F, Lawitz E, Hassanein T, et al. Sustained virologic response (SVR) results for weight-based- taribavirin versus weight-based-ribavirin in naive chronic-hepatitis C, genotype 1 patients. In: The 60th annual meeting of the American association for the study of liver diseases, Boston, 31 Oct-3 Nov 2009 [Hepatology 65]
12. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004; 56(11):819—24.
13. Gapinski MA, Zucker DM. Factors influencing the development of a hepatitis C exercise protocol: a literature review. Gastroenterol Nurs. 2005;28(3 Suppl): S10-8.
14. Costiniuk CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol. 2008;22(4): 376-80.
15. Salcedo-Mora X, Mate J, Medina J, Nam Cha SJ, Gisbert JP, Moreno-Otero R. Chronic hepatitis C and Crohn’s disease: nosocomial infection treatment with PEG-interferon plus ribavirin. Digestion. 2006;73(4): 210-4.
16. Scherzer TM, Staufer K, Novacek G, et al. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008;28(6):742-8.
17. Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40(6): 1450-8.
18. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580-93.
19. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginter- feron, ribavirin, and epoetin alpha. Hepatology. 2007;46(2):371-9.
20. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007; 2(6): 1274-82.
21. Costiniuk CT, Camacho F, Cooper CL. Erythropoiesis- stimulating agent use for anemia induced by interferonribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death. Clin Infect Dis. 2008;47(2):198-202.
22. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis. 2006;42(12):1674-8.
23. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357(22):2227-36.
24. Akamatsu S, Asazuma A, Kanamaru S, Takenawa J, Soeda A. Immune thrombocytopenia during interferonalfa therapy for renal cell carcinoma. Hinyokika Kiyo. 2006;52(10):789-92.
25. Deuffic S, Poynard T, Valleron AJ. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat. 1999;6(5):411-3.
26. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558—67.
27. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut. 2000; 47(6):845-51.
28. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357(2):124-34.
29. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40 Suppl 5:S276-85.
30. McLaren M, Garber G, Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can J Gastroenterol. 2008;22(2): 133-7.
31. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127(5 Suppl 1):S27-34.
32. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep. 2005; 7(5):391-5.
33. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002; 36(5): 1273-9.
34. Bonkovsky HL, Snow KK, Malet PF, et al. Health- related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46(3): 420-31.
35. Dove LM, Rosen RC, Ramcharran D, et al. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology. 2009;137(3):873-84. 884e1.
36. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3): 326-34.
37. Yamamoto T, Katayama I, Nishioka K. Psoriasis and hepatitis C virus. Acta Derm Venereol. 1995;75(6): 482-3.
38. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36(4):1051-66. x-xi.
39. Proceedings of the European association for the study of the liver international consensus conference on hepatitis C. Paris, France, 26-27 Feb 1999. J Hepatol. 1999;31 Suppl 1:4.
40. Proceedings of the European association for the study of the liver international consensus conference on hepatitis C. Paris, France, 26-27 Feb 1999. J Hepatol. 1999;31 Suppl 1:7.
41. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003; 13(6): 547-51.
42. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest. 2002;25(7):624-30.
43. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuetara AM, Jimenez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 2008;7(1):72-7.
44. Tarantino G, Gagliardi G, Conca P. Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? Int J Immunopathol Pharmacol. 2008;21(2):467-9.
45. Lo YC, Chang SY, Sheng WH, Hung CC, Chang SC. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature. Eur J Gastroenterol Hepatol. 2009;21 (4):478-81.
46. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther. 2003;18(6):549-58.
47. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002;32(3): 163-73.
48. Goldberg HJ, Fiedler D, Webb A, Jagirdar J, Hoyumpa AM, Peters J. Sarcoidosis after treatment with interferon-alpha: a case series and review of the literature. Respir Med. 2006;100(11):2063-8.
49. Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci. 2010;55(3):579-85.
50. Macedo G, Ribeiro T. Interferon plus ribavirin: a cautionary note. Am J Gastroenterol. 1999; 94(10):3087-8.
51. Boonen A, Stockbrugger RW, van der Linden S. Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol. 1999;18(2): 177-9.
52. Condat B, Asselah T, Zanditenas D, et al. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2006;18(3):287-9.
53. Kwo P, Lawitz E, McCone J, et al. Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients: interim results from the HCV SPRINT-1 study. In: 59th annual meeting of the American association for the study of liver diseases (AASLD), San Francisco, CA, 31 Oct-4 Nov 2008 [LB16].
54. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-50.
55. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18):1827-38.
56. Gane E, Roberts S, Stedman C, et al. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. In: 44th annual meeting of the European association for the study of the liver, Copenhagen, Denmark, 22-26 April 2009 [1046]
57. Grunberger C, Wyles DL, Kaihara KA, Schooley RT. 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. J Infect Dis. 2008;197(1):42-5.